Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Current Opinion in Neurology
|
January 20, 2021
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Antoine Leuzy, Nicholas C Cullen, Niklas Mattsson-Carlgren, et al.
JAMA Neurology
|
April 23, 2019
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson, Nicholas C Cullen, Ulf Andreasson, et al.
Scientific Reports
|
January 22, 2021
Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition
Nicholas C Cullen, A Nders Mälarstig, Erik Stomrud, et al.
Brain Communications
|
March 17, 2023
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
Nicholas C Cullen, Shorena Janelidze, Erik Stomrud, et al.
Annals of Clinical and Translational Neurology
|
August 12, 2020
Comparing progression biomarkers in clinical trials of early Alzheimer's disease
Nicholas C Cullen, Henrik Zetterberg, Philip S Insel, et al.
BMC Neurology
|
December 12, 2018
Transient increase in CSF GAP-43 concentration after ischemic stroke
Åsa Sandelius, Nicholas C Cullen, Åsa Källén, et al.
Acta Neuropathologica
|
September 24, 2018
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease
Hlin Kvartsberg, Tammaryn Lashley, Christina E Murray, et al.
Nature Communications
|
June 12, 2021
Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
Nicholas C Cullen, Antoine Leuzy, Shorena Janelidze, et al.
Journal of Neurology
|
May 25, 2019
NFL is a marker of treatment response in children with SMA treated with nusinersen
Bob Olsson, Lars Alberg, Nicholas C Cullen, et al.
Ebiomedicine
|
December 15, 2023
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial
Nicholas C Cullen, Petr Novak, Duygu Tosun, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Current Opinion in Neurology
|
January 20, 2021
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Antoine Leuzy, Nicholas C Cullen, Niklas Mattsson-Carlgren, et al.
JAMA Neurology
|
April 23, 2019
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson, Nicholas C Cullen, Ulf Andreasson, et al.
Scientific Reports
|
January 22, 2021
Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition
Nicholas C Cullen, A Nders Mälarstig, Erik Stomrud, et al.
Brain Communications
|
March 17, 2023
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
Nicholas C Cullen, Shorena Janelidze, Erik Stomrud, et al.
Annals of Clinical and Translational Neurology
|
August 12, 2020
Comparing progression biomarkers in clinical trials of early Alzheimer's disease
Nicholas C Cullen, Henrik Zetterberg, Philip S Insel, et al.
BMC Neurology
|
December 12, 2018
Transient increase in CSF GAP-43 concentration after ischemic stroke
Åsa Sandelius, Nicholas C Cullen, Åsa Källén, et al.
Acta Neuropathologica
|
September 24, 2018
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease
Hlin Kvartsberg, Tammaryn Lashley, Christina E Murray, et al.
Nature Communications
|
June 12, 2021
Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
Nicholas C Cullen, Antoine Leuzy, Shorena Janelidze, et al.
Journal of Neurology
|
May 25, 2019
NFL is a marker of treatment response in children with SMA treated with nusinersen
Bob Olsson, Lars Alberg, Nicholas C Cullen, et al.
Ebiomedicine
|
December 15, 2023
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial
Nicholas C Cullen, Petr Novak, Duygu Tosun, et al.
Page
of 3